CIK 0000072444
- Accelerated filer
- Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 591212264
- Phone
- +1 650-550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2010-04-05 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Sale | −1,520 | $5.32 | $8K | 115,852 |
| 2010-04-05 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Sale | −700 | $5.34 | $4K | 115,152 |
| 2010-04-05 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Sale | −200 | $5.36 | $1K | 114,952 |
| 2010-04-05 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Sale | −500 | $5.37 | $3K | 114,452 |
| 2010-04-05 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Sale | −600 | $5.38 | $3K | 113,852 |
| 2010-04-05 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Sale | −600 | $5.39 | $3K | 113,252 |
| 2010-04-01 | Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops | Grant or award | +24,000 | 53,650.1 | ||
| 2010-04-01 | Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops | Sale | −250 | $5.48 | $1K | 53,400.1 |
| 2010-04-01 | Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops | Sale | −400 | $5.48 | $2K | 53,000.1 |
| 2010-04-01 | Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops | Sale | −1,300 | $5.49 | $7K | 51,700.1 |
| 2010-04-01 | Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops | Other disposition | −2,100 | $5.49 | $12K | 49,600.1 |
| 2010-04-01 | Kalnik Matthew W. SVP Strategic Plan. & Bus. Ops | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2010-04-01 | FAHIM RAAFAT E F President, CEO and CFO | Grant or award | +50,000 | 333,818.94 | ||
| 2010-04-01 | FAHIM RAAFAT E F President, CEO and CFO | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2010-04-01 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Grant or award | +36,000 | 118,500 | ||
| 2010-04-01 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2010-03-24 | Aryeh Jason Director | Sale | −234 | $6.24 | $1K | 251,883 |
| 2010-03-23 | Aryeh Jason Director | Sale | −64,793 | $6.25 | $405K | 252,117 |
| 2010-03-22 | Aryeh Jason Director | Sale | −28,510 | $6.24 | $178K | 316,910 |
| 2010-03-19 | Aryeh Jason Director | Sale | −7,800 | $5.99 | $47K | 345,420 |
Page 30 of 42 · 830 trades